IDEAYA Biosciences, Inc. IDYA
26.49 USD -0.91 (-3.32%)
Regular-session close
26.49 0.00 0.00%
After hours · Nov 18, 4:40 PM ET
26.02 Day range 27.53
26.49 52-week range 42.48
- YTD
- -23.37%
- 1 year
- -21.42%
News
defenseworld.net IDEAYA Biosciences, Inc. $IDYA Shares Bought by Aberdeen Group plc Aberdeen Group plc raised its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 5.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned…
seekingalpha.com Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More I maintain a 'Strong Buy' on Ideaya Biosciences, Inc.: the darovasertib NDA submission is complete, while IDE849 offers multiple registrational opportunities. Darovasertib plus crizotinib targets…benzinga.com RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $45 Price Target RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.
prnewswire.com IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple…
seekingalpha.com IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027 Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's…
gurufocus.com IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid TumorsPR News
prnewswire.com IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's…benzinga.com Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39 Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $44 to $39.
benzinga.com Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66 Citigroup analyst Yigal Nochomovitz maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $65 to $66.
benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.
benzinga.com Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57 Truist Securities analyst Gregory Renza reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $59 to $57.
benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $57 to $52.
benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $63 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $60 to $63.
prnewswire.com IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
zacks.com IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to earnings of $1.33 per share a year ago.benzinga.com IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.18) by 4.27 percent. This is a 191.73 percent decrease over earnings…
prnewswire.com IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic…
prnewswire.com IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization…
zacks.com IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell? IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $34.19 and traded…
prnewswire.com IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas 17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5%…benzinga.com IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and…
prnewswire.com IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of…
defenseworld.net IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, October 6th. The shares were sold…
defenseworld.net IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s stock price traded up 4.8% on Monday. The company traded as high as $38.38 and last traded at $38.45. Approximately 278,808 shares traded…
prnewswire.com IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
prnewswire.com IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted…
defenseworld.net Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
seekingalpha.com IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
